A-443654Akt inhibitor,potent and selective CAS# 552325-16-3 |
- PHT-427
Catalog No.:BCC2554
CAS No.:1191951-57-1
- AT7867 dihydrochloride
Catalog No.:BCC1378
CAS No.:1431697-86-7
- Perifosine
Catalog No.:BCC3673
CAS No.:157716-52-4
- TIC10
Catalog No.:BCC3906
CAS No.:41276-02-2
- A-674563
Catalog No.:BCC3903
CAS No.:552325-73-2
- CCT128930
Catalog No.:BCC3904
CAS No.:885499-61-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 552325-16-3 | SDF | Download SDF |
PubChem ID | 10172943 | Appearance | Powder |
Formula | C24H23N5O | M.Wt | 397.48 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (251.59 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | (2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine | ||
SMILES | CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OCC(CC4=CNC5=CC=CC=C54)N | ||
Standard InChIKey | YWTBGJGMTBHQTM-IBGZPJMESA-N | ||
Standard InChI | InChI=1S/C24H23N5O/c1-15-22-10-16(6-7-24(22)29-28-15)17-9-20(13-26-11-17)30-14-19(25)8-18-12-27-23-5-3-2-4-21(18)23/h2-7,9-13,19,27H,8,14,25H2,1H3,(H,28,29)/t19-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | A-443654 is a potent and selective inhibitor of Akt1 with Ki value of 160 pM. | |||||
Targets | Akt1 | |||||
IC50 | 160 pM (Ki) |
A-443654 Dilution Calculator
A-443654 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5158 mL | 12.5792 mL | 25.1585 mL | 50.317 mL | 62.8962 mL |
5 mM | 0.5032 mL | 2.5158 mL | 5.0317 mL | 10.0634 mL | 12.5792 mL |
10 mM | 0.2516 mL | 1.2579 mL | 2.5158 mL | 5.0317 mL | 6.2896 mL |
50 mM | 0.0503 mL | 0.2516 mL | 0.5032 mL | 1.0063 mL | 1.2579 mL |
100 mM | 0.0252 mL | 0.1258 mL | 0.2516 mL | 0.5032 mL | 0.629 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
A-443654 is a potent and selective inhibitor of Akt with Ki value of 160 pM [1].
The Akt kinases play important roles in cellular signal transduction and take participate in the regulation of cell transformation and tumor progression. The activities of them are usually elevated in human malignancies. A-443654 is a pan inhibitor of Akt1, 2 and 3. It binds to the ATP-binding site of Akt and inhibits the kinase activity reversibly. A-443654 shows selectivity against Akt. The inhibition ability of it for Akt is much higher than that for other kinases. It is found that A-443654 can suppress the phosphorylation of the downstream proteins of Akt while increased the Ser473 and Thr308 phosphorylation of Akt [1].
In murine FL5.12 cells stably transfected with human Akt1, 2 or 3, A-443654 inhibited the phosphorylation of GSK3 dose-dependently. A-443654 at a concentration of 0.6 μM inhibited Akt and induced G2/M accumulation in H1299 cells. In MiaPaCa-2 cells, treatment of A-443654 for 48 h resulted in a suppression of tumor proliferation with EC50 value of 100 nM. In chronic lymphocytic leukemia cells, A-443654 also inhibited the activity of Akt and induced apoptosis with EC50 value of 0.63 μM .Besides that, A-443654 was found to cause decreased phosphorylation of GSK3, FOXO3, TSC2 and mTOR in MiaPaCa-2 cells. It is also reported that A-443654 was effective in blocking the phosphorylation of 4EBP-1 and S6 protein in both T47D and LNCaP cells [1, 2, 3 and 4].
A-443654 is not oral available. In mice model with human MiaPaCa-2 pancreatic cell xenograft, the administration of A-443654 at a dose of 7.5mg/kg/d significantly inhibited tumor growth. A-443654 also inhibited tumor growth in 3T3 murine fibroblast model expressing active Akt. When using the combination of A-443654 and rapamycin in mice model with MiaPaCa-2 pancreatic cancer xenograft, the administration showed more efficacy than each monotherapy [1].
References:
1.Luo Y, Shoemaker A R, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Molecular cancer therapeutics, 2005, 4(6): 977-986.
2.Liu X, Shi Y, Woods K W, et al. Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia, 2008, 10(8): 828-837.
3.Merce de Frias M, Iglesias-Serret D, Cosialls A M, et al. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. haematologica, 2009, 94(12): 1698-1707.
4.Cherrin C, Haskell K, Howell B, et al. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer biology & therapy, 2010, 9(7): 493-503.
- T16Ainh - A01
Catalog No.:BCC6220
CAS No.:552309-42-9
- Vallesiachotamine
Catalog No.:BCN3548
CAS No.:5523-37-5
- Rolapitant
Catalog No.:BCC6441
CAS No.:552292-08-7
- AP 18
Catalog No.:BCC7634
CAS No.:55224-94-7
- Dexamethasone Sodium Phosphate
Catalog No.:BCC4557
CAS No.:55203-24-2
- Sasapyrine
Catalog No.:BCC4714
CAS No.:552-94-3
- Daidzin
Catalog No.:BCN5891
CAS No.:552-66-9
- Prunetin
Catalog No.:BCN2335
CAS No.:552-59-0
- Eriodictyol
Catalog No.:BCN1209
CAS No.:552-58-9
- Isorhoifolin
Catalog No.:BCN5739
CAS No.:552-57-8
- Paeonol
Catalog No.:BCN5738
CAS No.:552-41-0
- Oxohydrastinine
Catalog No.:BCN3299
CAS No.:552-29-4
- A-674563
Catalog No.:BCC3903
CAS No.:552325-73-2
- Boc-Gln(Xan)-OH
Catalog No.:BCC3385
CAS No.:55260-24-7
- MnTBAP Chloride
Catalog No.:BCC6477
CAS No.:55266-18-7
- Praziquantel
Catalog No.:BCC4829
CAS No.:55268-74-1
- Atractylodin
Catalog No.:BCN6292
CAS No.:55290-63-6
- (Z)-Falcarindiol
Catalog No.:BCN8495
CAS No.:55297-87-5
- Tiamulin
Catalog No.:BCC9179
CAS No.:55297-95-5
- Thonzonium Bromide
Catalog No.:BCC5636
CAS No.:553-08-2
- Xanthyletin
Catalog No.:BCN6722
CAS No.:553-19-5
- Costunolide
Catalog No.:BCN5740
CAS No.:553-21-9
- Atherosperminine
Catalog No.:BCN8208
CAS No.:5531-98-6
- Soyasaponin II
Catalog No.:BCN1418
CAS No.:55319-36-3
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition.[Pubmed:17334390]
Oncogene. 2007 Aug 16;26(38):5655-61.
Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis. We report that A-443654, a potent small-molecule inhibitor of Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines tested, including PTEN- and TSC2-deficient lines. This phenomenon is dose-dependent, manifests coincident with Akt inhibition and likely represents an alternative, rapid-feedback pathway that can be functionally dissociated from mTORC1 inhibition. Experiments performed in TSC2-/- cells indicate that TSC2 and IRS-1 cooperate with, but are dispensable for, A-443654-mediated Akt phosphorylation. This feedback event does require PI3K activity, however, as it can be inhibited by LY294002 or wortmannin. Small interfering RNA-mediated knockdown of mTOR or Rictor, components of the rapamycin-insensitive mTORC2 complex, but not the mTORC1 component Raptor, also inhibited Akt Ser-473 phosphorylation induced by A-443654. Our data thus indicate that Akt phosphorylation and activity are coupled in a manner not previously appreciated and provide a novel mode of Akt regulation that is distinct from the previously described rapamycin-induced IRS-1 stabilization mechanism.
Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression.[Pubmed:18670641]
Neoplasia. 2008 Aug;10(8):828-37.
Both Akt and Aurora A kinase have been shown to be important targets for intervention for cancer therapy. We report here that Compound A (A-443654), a specific Akt inhibitor, interferes with mitotic progression and bipolar spindle formation. Compound A induces G(2)/M accumulation, defects in centrosome separation, and formation of either monopolar arrays or disorganized spindles. On the basis of gene expression array studies, we identified Aurora A as one of the genes regulated transcriptionally by Akt inhibitors including Compound A. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, either by PI3K inhibitor LY294002 or by Compound A, dramatically inhibits the promoter activity of Aurora A, whereas the mammalian target of rapamycin inhibitor has little effect, suggesting that Akt might be responsible for up-regulating Aurora A for mitotic progression. Further analysis of the Aurora A promoter region indicates that the Ets element but not the Sp1 element is required for Compound A-sensitive transcriptional control of Aurora A. Overexpression of Aurora A in cells treated with Compound A attenuates the mitotic arrest and the defects in bipolar spindle formation induced by Akt inhibition. Our studies suggest that that Akt may promote mitotic progression through the transcriptional regulation of Aurora A.